Back to today’s briefing

Story perspectives

Goldman Sachs Boosts Carlsmed and McGraw Hill Ratings

8/19/2025

37 7

Summary

Story summary

Goldman Sachs assigned buy ratings to Carlsmed and McGraw Hill, targeting $19 and $27, respectively.
UBS upgraded CVS to buy, indicating signs of recovery.
CSX Corp. was downgraded to market perform due to merger speculation.
Desjardins increased Automotive Properties' price target, citing positive acquisition activity.
Analysts express caution on Conifex Timber due to maintenance downtimes but recognize potential government support benefits.

1 of 1

Story summary

Goldman Sachs assigned buy ratings to Carlsmed and McGraw Hill, targeting $19 and $27, respectively.
UBS upgraded CVS to buy, indicating signs of recovery.
CSX Corp. was downgraded to market perform due to merger speculation.
Desjardins increased Automotive Properties' price target, citing positive acquisition activity.
Analysts express caution on Conifex Timber due to maintenance downtimes but recognize potential government support benefits.